Cyprotex performance holds steady

DRUG discovery firm Cyprotex has said it expects its full year results to be in line with market expectations, with revenues on a par with 2008.

The Macclesfield firm said in a trading statement that levels of activity in November and December 2009 has been “solid”.

In its previous trading statement, published in November, the AIM-listed company said there had been less work from existing clients, including its largest customer, but new business enquiries had been more buoyant.

Cyprotex will report its results for the year to the end of December on March 17.